Biogen (BIIB)
(Delayed Data from NSDQ)
$230.57 USD
+0.53 (0.23%)
Updated May 17, 2024 04:00 PM ET
After-Market: $230.64 +0.07 (0.03%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth B Momentum B VGM
Brokerage Reports
Biogen Inc. [BIIB]
Reports for Purchase
Showing records 541 - 560 ( 799 total )
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Comprehensive Technical and Fundamental Analysis for BIIB.
Provider: Stock Traders Daily
Analyst: Research Department
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Comprehensive Technical and Fundamental Analysis for BIIB.
Provider: Stock Traders Daily
Analyst: Research Department
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Comprehensive Technical and Fundamental Analysis for BIIB
Provider: Stock Traders Daily
Analyst: Research Department
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Comprehensive Technical and Fundamental Analysis for BIIB
Provider: Stock Traders Daily
Analyst: Research Department
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Comprehensive Technical and Fundamental Analysis for BIIB
Provider: Stock Traders Daily
Analyst: Research Department
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Vumerity Comes Out Ahead Vs. Tecfidera, But Unlikely To Move Near-Term Needle
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
An Update on Tecfideras IP Situation Following IP Attorney Diligence
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Provider: Zacks Investment Research
Analyst: Research Department
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Following Science - Following Genetics; Reit Buy and $300 PT
Provider: H.C. Wainwright & Co., Inc.
Analyst: FEIN A
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Looking Beyond the Beat and Raise: What''s Coming Next?
Provider: WEDBUSH SECURITIES INC.
Analyst: CHICO L
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
First Take 2Q19 Report: Revenue, EPS Beat; All Eyes On Competitive Landscape
Provider: WEDBUSH SECURITIES INC.
Analyst: Research Department
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Comprehensive Technical and Fundamental Analysis for BIIB
Provider: Stock Traders Daily
Analyst: Research Department
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
Biotechnology - Ahead of 2Q19 Biotech Reporting - Thoughts on Commercial Names
Provider: WEDBUSH SECURITIES INC.
Company: Biogen Inc.
Industry: Medical - Biomedical and Genetics
HEALTHCARE - The Week Ahead in Life Sciences
Provider: WEDBUSH SECURITIES INC.
Analyst: NIERENGARTEN D